Vifor Pharma (Germany)

Vifor Pharma (Germany)

CSL Vifor is a global specialty pharmaceuticals company in the treatment areas of iron deficiency, dialysis, nephrology & rare disease. It is headquartered in Switzerland and consists of CSL Vifor, Vifor Fresenius Medical Care Renal Pharma and Sanifit Therapeutics. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for Vifor Pharma (Germany), Germany, covering academic research published from 2001 to 2023. Read More.


Open Access Percentage

62%


Total
Publications

53


Total Open
Publications

33


Total
Citations

1.4K


Open Access
Percentage

62%


Total
Publications

53


Total Open
Publications

33


Total
Citations

1.4K

Wikipedia

Website

download

Breakdown

34% 22% 6% 38%

Publisher Open

34%

Both

22%

Other Platform Open

6%

Closed

38%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
20012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

00.511.522.533.544.555.566.57Total Publications
20012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Open

Closed

Publisher Open

27%OA Journal

OA Journal 27%

8

Hybrid 30%

9

No Guarantees 43%

13

Other Platform Open

Domain 87%

13

Public 27%

4

Institution 20%

3

Preprint 7%

1

Other Internet 0%

0

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
13
Europe PMC
Domain
10
Semantic Scholar
Public
4
University of Zurich - Zurich Open Repository and Archive
Institution
1
University of Groningen / Centre for Information Technology - University of Groningen research database
Institution
1
Research Square
Preprint
1
Goethe University Frankfurt - Publication Server of Goethe University Frankfurt am Main
Institution
1
DANS - Data Archiving and Networked Services - NARCIS - National Academic Research and Collaborations Information System
Institution
1
1 / 1

Data updated 17 June 2024

Share

Share

Share